Dimension Therapeutics Announces Presentation at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced a poster presentation that highlights Dimension’s leadership in the development of improved AAV-based vectors for diverse therapeutic applications. Preclinical in vivo research conducted with Dimension’s collaborators at the University of Pennsylvania (Penn) demonstrates that the choice of capsid, a key component of AAV vectors, has a significant impact on both product efficiency and immunogenicity in preclinical studies relating to liver gene therapy. The poster presentation will take place during the 58th ASH Annual Meeting, which is being held in San Diego, California, December 3-6, 2016.

“We are excited to present data at this year’s ASH conference that will highlight research supporting the choice of AAV capsids for our broad product development pipeline in metabolic diseases and hemophilia,” said Dr. Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension. “These findings, resulting from a highly productive translational research collaboration with the lab of James Wilson, MD, PhD, a professor of Medicine and Pediatrics in the Perelman School of Medicine at Penn, demonstrate our commitment to generating and communicating important data that supports the translation of gene therapy science into the clinic.”

The poster presentation details are as follows:

Title: Strategies for Selection of AAV Vectors for Administration to Liver: Studies in Nonhuman Primates (Abstract #2316)
Session: 801. Gene Therapy and Transfer: Poster I
Date: Saturday, December 3, 2016
Presentation Time: 5:30 PM - 7:30 PM Pacific Time
Location: San Diego Convention Center, Hall GH
Authors: Lili Wang1, Roberto Calcedo1, Peter Bell1, Zhenning He1, John White1, Matthew M Hewitt1, Leah Makaron1, Lisa Kattenhorn2, Samuel Wadsworth2, Tamara Goode1, and James M Wilson1 1Gene Therapy Program, Department of Medicine, University of Pennsylvania; 2Dimension Therapeutics, Inc.

Penn, Wilson and Wadsworth are each holders of Dimension stock, and Wilson also holds stock in REGENXBIO, Inc. Dimension holds exclusive sublicenses from REGENXBIO, Inc. for certain PENN-owned AAV technologies related to this development program.

About Dimension Therapeutics

Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.

For more information, please visit http://www.dimensiontx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding development, preclinical results and the continued progress of Dimension’s portfolio and programs. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Dimension's product candidates, including its lead candidate, DTX101, will not successfully be developed or commercialized; and the risks described under the caption "Risk Factors" in Dimension Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Dimension Therapeutics’ additional filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Dimension Therapeutics undertakes no duty to update this information unless required by law.

CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 jean.franchi@dimensiontx.com Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 jjackson@burnsmc.com

Source:Dimension Therapeutics